Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Carmot Therapeutics is raising $160,671,809.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Stig Hansen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Carmot Therapeutics
Carmot Therapeutics, Inc. is a clinical-stage company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative, patented drug discovery approach, Chemotype Evolution to explore novel frontiers of chemistry and biology. Using Chemotype Evolution, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.

To learn more about Carmot Therapeutics, visit http://carmot-therapeutics.us/

Contact:
Stig Hansen, Chief Executive Officer
888-402-4674
https://www.linkedin.com/in/stig-hansen-6988568/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved